This relative simplicity has encouraged further interest in studying the peptide as a research tool for receptor-specific interactions
Assuming that the percentage of patients showing an increase in serum vitamin B12 concentration to above 179 pg/ml in both groups is 70%, means the study requires at least 304 patients (152 in each arm) for a threshold of non-inferiority of 10% and a statistical power of 60% with significance set at p 179 pg/ml: patient preference questionnaire Randomisation of patients to treatment group Visit 1 (start of treatment) Anamnesis: record whether the patient lives alone or with others, lifestyle habits, use of alcohol, whether a vegan diet is followed, whether the patient has undergone gastrectomy Symptoms: record paresthesia, asthenia, loss or reduction of appetite, sadness or change in state of mind, concomitant pharmacological treatment Physical examination: for Hunters glositis, positional and vibrational sensitivity Questionnaires: Lobo cognitive mini-exam, EuroQoL-5D Record concomitant treatment Request analyses to be performed one week before next visit: haemogram and serum vitamin B12 Therapeutic plan: patient in oral arm provision of medication
Proper storage of BPC-157 is essential to preserve its structural integrity and biological activity for laboratory use
The GRAS determination was likely based on the compound's limited systemic absorption (when ingested), short plasma half-life, and lack of acute toxicity signals in the Phase 2b obesity trial
You are receiving or have been advised high-dose B12 therapy and want to monitor your levels
For instance, a patient with borderline low B-vitamin levels might receive 0.5 mL IM weekly, whereas someone with severe malabsorption could receive 1-2 mL IM two to three times per week initially
